In Brief: U.S. Surgical/American BioMed
This article was originally published in The Gray Sheet
Executive Summary
U.S. Surgical/American BioMed: Enter agreement under which USS will have a 90-day option to buy American BioMed's technologies for vascular stents, atherectomy and toposcopic catheters and all related intellectual property, the firms announce May 2. USSC paid $2 mil. for the option and will pay an additional $12 mil. upon finalization of the deal, according to American BioMed...